Creabilis adds three executives to management team
Reflects growing confidence in pipeline and science that underpins it
Alex Leech joins as vice president, head of finance and operations, James Sandy as senior vice president, head of development, and Peter Spargo as senior vice president for chemistry manufacturing and controls (CMC).
Leech was most recently head of operations at Solace Pharmaceuticals. Prior to this, he worked for the Pfizer r&d organisation where he was head of European project management. He has also held a number of operational and engineering management roles at Ford. Sandy was most recently at Pfizer as development team leader of Pfizer’s GI portfolio. Prior to working at Pfizer, he was head of biometrics at Astra UK.
Spargo was most recently at Novexel as senior vice president of CMC. Prior to this he was head of chemical process r&d for Pfizer in Europe.
Eliot Forster, ceo of Creabilis, said: ‘This expansion of our senior management team reflects Creabilis’ growing maturity and the confidence we have in our pipeline, our science and the culture that underpins it.’
You may also like
Research & Development
Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent
Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development
Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide
Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial
BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
Research & Development
Indena and TCG GreenChem join forces to advance next-generation ADC technologies
Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers: the key component of antibody-drug conjugates (ADCs)